Clinical Trial Update: Bioequivalence Study of BAY77-1931 Granule [Phase 1]

View source ↗

Summary

This document reports the completion of a Phase 1 bioequivalence study of BAY77-1931 Granule for hyperphosphatemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperphosphatemia

Drugs mentioned

• BAY77-1931 Granule (BAY77-1931)

Snippet

Sponsor: Bayer | Conditions: Hyperphosphatemia | Phase 1 | Status: COMPLETED